The IND landscape is shifting after a period of constrained early-stage funding and reduced activity. Grants and private investment are returning, and development programs that stalled are moving again. Sponsors entering 2026 with plans to file an IND have broader access to capacity but face a more complex environment for vendor selection, resource planning, and long-term strategy. Olon USA supports these programs with a development approach built for scalability, consistency, and technical depth.
Early Strategic Decisions Shape the Entire Program
The first decisions sponsors make determine the efficiency and cost of downstream development. Sponsors need a clear view of their objectives: whether the asset is being positioned for acquisition or for full internal development. Each strategy drives different expectations for process robustness, documentation, and scalability.
Some sponsors choose low-cost early providers to conserve capital. This route often leads to re-development during scale-up because early processes were not engineered for clinical scale. Re-development can introduce new impurities and new analytical work, placing timelines at risk. A development partner capable of designing a scalable process from the first gram avoids these inefficiencies.
Differences in IND Readiness Across Organizations
Established pharma teams typically understand the costs, timelines, and risks associated with the IND process. Virtual biotechs and first-time founders can underestimate the investment required to reach each milestone. Gaps in planning often emerge around analytical needs, toxicology material, and the sequence of scale-up activities.
Olon USA supports teams unfamiliar with IND execution by outlining the technical path, identifying risk points, and advising when external regulatory expertise is required. A broad consultant network is available when specialized guidance is needed outside the scope of synthetic chemistry and API development.
Commercial Scalability Must Be Considered at the Earliest Stage
Commercial readiness begins at the gram scale. Every reaction step used to generate milligram or gram quantities should be designed with its future kilogram version in mind. Early design choices directly affect yield, impurity profiles, and the viability of toxicology batches and clinical supply.
Sponsors who treat IND material as a stand-alone effort often face delays when they attempt to scale to clinical or commercial levels. A consistent development partner eliminates redundant work and maintains continuity across each escalation in batch size.
Avoiding Costly Mistakes in Early Development
Formulation work is often misprioritized. Many emerging pharma teams invest heavily in formulation before generating proof of efficacy or a fully developed API process. Unless the program includes unusual solubility constraints, basic formulations such as powder-in-capsule are sufficient through early clinical phases.
Focusing resources on API development and scalable synthesis protects the program from delays and prevents premature allocation of limited capital.
Planning for 2026 IND Submissions
Supply chain lead times remain extended. Sponsors targeting Q1–Q2 toxicology studies in 2026 should have API production already underway. Starting materials and intermediates require longer timelines due to import scrutiny, tariffs, and customs processes. Early alignment with a development partner reduces the likelihood of scheduling disruptions.
What Differentiates Olon USA
Olon USA provides small-scale development capabilities and large-scale manufacturing within a single site. Batch execution ranges from milligrams to approximately 150 kilograms, with our new reactor capacity being added. The site supports non-GLP, GLP, GMP clinical, and commercial manufacturing for small molecules.
The facility has operated in API development and manufacturing since 1986 and has expanded its scientific and technical resources through integration with the global Olon Group. The site provides analytical testing, polymorph screening, forced degradation studies, salt selection, and physical-chemical characterization. This consolidated model reduces vendor handoffs and keeps critical activities within a single development ecosystem.
Start the Conversation
Sponsors preparing for IND initiation in 2026 can strengthen their programs through early engagement and clear technical planning. Olon USA offers scalable development, extensive analytical capabilities, and decades of manufacturing experience.
Organizations seeking a reliable partner for IND-enabling API development are encouraged to contact Olon USA to begin a discussion about their project.